TANGO THERAPEUTICS INC (TNGX)
US87583X1090 - Common Stock
TNGX gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 561 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for TNGX as it has an excellent financial health rating, but there are worries on the profitability. TNGX is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
TNGX had negative earnings in the past year.
In the past year TNGX has reported a negative cash flow from operations.
In the past 5 years TNGX always reported negative net income.
TNGX had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
TNGX has a better Return On Assets (-35.01%) than 62.34% of its industry peers.
TNGX has a better Return On Equity (-53.84%) than 64.32% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -35.01% | ||
| ROE | -53.84% | ||
| ROIC | N/A |
ROA(3y)-20.57%
ROA(5y)N/A
ROE(3y)-33.48%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
TNGX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
TNGX does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, TNGX has more shares outstanding
There is no outstanding debt for TNGX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
Based on the Altman-Z score of -0.48, we must say that TNGX is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of TNGX (-0.48) is better than 61.08% of its industry peers.
TNGX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -0.48 |
ROIC/WACCN/A
WACC10.63%
2.3 Liquidity
TNGX has a Current Ratio of 8.00. This indicates that TNGX is financially healthy and has no problem in meeting its short term obligations.
With a decent Current ratio value of 8.00, TNGX is doing good in the industry, outperforming 72.79% of the companies in the same industry.
TNGX has a Quick Ratio of 8.00. This indicates that TNGX is financially healthy and has no problem in meeting its short term obligations.
TNGX has a better Quick ratio (8.00) than 72.97% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 8 | ||
| Quick Ratio | 8 |
3. Growth
3.1 Past
TNGX shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -6.31%.
Looking at the last year, TNGX shows a quite strong growth in Revenue. The Revenue has grown by 15.66% in the last year.
EPS 1Y (TTM)-6.31%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-17.39%
Revenue 1Y (TTM)15.66%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%8.15%
3.2 Future
Based on estimates for the next years, TNGX will show a decrease in Earnings Per Share. The EPS will decrease by -6.71% on average per year.
TNGX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 21.41% yearly.
EPS Next Y-11.34%
EPS Next 2Y-14.96%
EPS Next 3Y-11.07%
EPS Next 5Y-6.71%
Revenue Next Year18.42%
Revenue Next 2Y-14.25%
Revenue Next 3Y-13.5%
Revenue Next 5Y21.41%
3.3 Evolution
4. Valuation
4.1 Price/Earnings Ratio
TNGX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year TNGX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A cheap valuation may be justified as TNGX's earnings are expected to decrease with -11.07% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-14.96%
EPS Next 3Y-11.07%
5. Dividend
5.1 Amount
TNGX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
TANGO THERAPEUTICS INC
NASDAQ:TNGX (1/6/2025, 4:20:00 PM)
After market: 3.05 0 (0%)3.05
-0.1 (-3.17%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners90.41%
Inst Owner Change0%
Ins Owners1.52%
Ins Owner Change-9.26%
Market Cap327.63M
Analysts86.67
Price Target11.73 (284.59%)
Short Float %8.62%
Short Ratio3.71
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)29.86%
Min EPS beat(2)27.91%
Max EPS beat(2)31.8%
EPS beat(4)2
Avg EPS beat(4)9.26%
Min EPS beat(4)-12.95%
Max EPS beat(4)31.8%
EPS beat(8)6
Avg EPS beat(8)15.52%
EPS beat(12)8
Avg EPS beat(12)12.19%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)104.12%
Min Revenue beat(2)45.73%
Max Revenue beat(2)162.51%
Revenue beat(4)2
Avg Revenue beat(4)41.98%
Min Revenue beat(4)-35.41%
Max Revenue beat(4)162.51%
Revenue beat(8)4
Avg Revenue beat(8)37.44%
Revenue beat(12)5
Avg Revenue beat(12)25.47%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-28.68%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0.86%
EPS NY rev (1m)0%
EPS NY rev (3m)9.52%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-5.44%
Revenue NY rev (1m)0%
Revenue NY rev (3m)8.11%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 7.55 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.43 | ||
| P/tB | 1.43 | ||
| EV/EBITDA | N/A |
EPS(TTM)-1.18
EYN/A
EPS(NY)-1.45
Fwd EYN/A
FCF(TTM)-1.15
FCFYN/A
OCF(TTM)-1.14
OCFYN/A
SpS0.4
BVpS2.13
TBVpS2.13
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -35.01% | ||
| ROE | -53.84% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-20.57%
ROA(5y)N/A
ROE(3y)-33.48%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.12
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 34.32% | ||
| Cap/Sales | 1.97% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 8 | ||
| Quick Ratio | 8 | ||
| Altman-Z | -0.48 |
F-Score3
WACC10.63%
ROIC/WACCN/A
Cap/Depr(3y)248.42%
Cap/Depr(5y)N/A
Cap/Sales(3y)13.36%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-6.31%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-17.39%
EPS Next Y-11.34%
EPS Next 2Y-14.96%
EPS Next 3Y-11.07%
EPS Next 5Y-6.71%
Revenue 1Y (TTM)15.66%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%8.15%
Revenue Next Year18.42%
Revenue Next 2Y-14.25%
Revenue Next 3Y-13.5%
Revenue Next 5Y21.41%
EBIT growth 1Y-27.3%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-32.33%
EBIT Next 3Y-32.53%
EBIT Next 5YN/A
FCF growth 1Y-17.24%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-25.18%
OCF growth 3YN/A
OCF growth 5YN/A